
|Articles|October 1, 2012
Various factors dictate which neuromodulator to use, and when
As research and clinical experience continue to underscore differences between the three neuromodulators available in the United States, picking a product for a given clinical situation rests largely upon individual preference, according to Joel L. Cohen, M.D., who spoke earlier this year at MauiDerm 2012: Advances in Cosmetic and Medical Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
KT-621 in Atopic Dermatitis: What Early EASI and Pruritus Data Show
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Social Media Mythbusters: Skin Cycling
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














